Seaport Research has lowered its price target for Polaris Inc. (PII) following a strong fourth quarter overshadowed by softer-than-expected forward guidance. The firm maintains a Buy rating, citing the company's market share gains and operational improvements amidst ongoing tariff challenges.
After the COVID-19 windfall subsided, Pfizer CEO Albert Bourla is steering the pharmaceutical giant into a high-stakes, $23 billion pivot to cancer research. Facing a looming patent cliff and plummeting vaccine revenue, Bourla is betting on scientific innovation to secure the company's future—and redefine cancer treatment.
Haemonetics (NYSE:HAE) sees its price target raised by Barrington Research following its acquisition of Vivasure Medical, with analysts highlighting the deal's potential to bolster its medical device portfolio and drive growth.
Clinical-stage biopharma Alumis Inc. (ALMS) is gaining significant Wall Street attention after its lead drug candidate, envudeucitinib, successfully met all endpoints in key Phase 3 trials for plaque psoriasis, prompting multiple analyst upgrades and optimistic price targets.
Shares of Lionsgate Studios Corp. receive a vote of confidence from Seaport Research, which raised its price target following strong box office results. The move underscores broader analyst support for the newly independent content company's library monetization and strategic use of AI.
New research reveals a stark preparedness gap among UK manufacturers and wholesalers for the impending EU Digital Product Passport (DPP), with nearly half unaware of the regulation that could bar non-compliant goods from the single market.
A surge in housing supply, particularly across Sun Belt states, is creating prime conditions for homebuyers, with new research highlighting metros where inventory levels tip the scale in the buyer's favor.
Fresh financial data from QuidelOrtho reveals ongoing challenges, including constant currency revenue declines and pressured cash flow, forcing investors to weigh the stock's risk-reward profile as its momentum appears to fade.
French pharmaceutical giant Sanofi has discontinued development of its experimental mRNA flu vaccine, citing a strategic reprioritization. The decision comes as influenza activity remains high across much of the United States, with significant hospitalizations and deaths reported this season.
The FDA has issued a complete response letter for Aquestive Therapeutics' sublingual epinephrine film Anaphylm, citing concerns over packaging and user instructions. The company aims to address the issues and resubmit its application by the third quarter of this year.
IDEXX Laboratories (IDXX) reported robust double-digit growth for Q4 2025, driven by record placements of its premium diagnostic instruments and expanding test utilization. While acknowledging persistent softness in U.S. veterinary visit volumes, the company outlined a confident initial 2026 forecast, banking on its innovation pipeline and the transformative impact of its inVue Dx system.
New research reveals a stark disconnect: while a majority of firms are ramping up investment in incentive pay to fuel growth, widespread execution errors are rendering these costly programs ineffective, leaving potential revenue on the table.
IDEXX Laboratories reports robust fourth-quarter and full-year 2025 results, with double-digit revenue growth fueled by record instrument placements and strategic innovations like InVue DX and CancerDx. The company provides a confident outlook for 2026, targeting continued organic growth despite sector headwinds.
Barclays initiates coverage with an Overweight rating and $20 price target on Altimmune, citing strong fundamentals and pipeline potential. The biotech firm prepares to channel recent offering proceeds toward its pivotal Phase 3 development for metabolic liver disease treatment pemvidutide.
Piper Sandler and Barclays have raised price targets for CytomX Therapeutics (CTMX), citing promising early-phase data for its experimental colorectal cancer therapy. Updated results from a larger patient cohort are expected this quarter.
The Apis Flagship Fund reported robust quarterly and annual gains for 2025, significantly beating global benchmarks. While highlighting its performance drivers, the fund's investor letter also discussed its position on gene therapy firm uniQure (QURE).
Edwards Lifesciences (NYSE: EW) has terminated its planned takeover of JenaValve, opting instead to reinvest capital into its internal transcatheter aortic (TAVR) and mitral valve development programs. The strategic pivot underscores a renewed focus on organic growth in its core structural heart business.
The medtech giant inaugurates a Centre of Excellence in Swords, aiming to accelerate development of its Atellica diagnostic systems and bolster Ireland's life sciences sector amid strategic corporate shifts.
Pharmaceutical giant Eli Lilly enters a strategic collaboration potentially worth up to $1.93 billion with biotech firm Repertoire Immune Medicines, aiming to develop precision treatments for autoimmune diseases that move beyond broad immunosuppression.
The European CE Mark under the stringent MDR has been granted for Cynosure Lutronic's innovative fractional resurfacing system, designed to improve safety and patient comfort through advanced cooling and precision technology.
